<DOC>
	<DOCNO>NCT02807454</DOCNO>
	<brief_summary>This open-label , multicenter study confirm safety efficacy durvalumab + daratumumab ( D2 ) subject relapse refractory multiple myeloma . This study also explore safety efficacy addition pomalidomide + dexamethasone durvalumab + daratumumab ( PD3 ) .</brief_summary>
	<brief_title>A Study Determine Safety Efficacy Combination Durvalumab Daratumumab Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Daratumumab</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Must measurable disease define mprotein serum free light chain . Must fail last line treatment ( refractory last line treatment ) . Must achieve least minimal response ( MR ) least 1 prior antimyeloma regimen develop PD ( relapse ) Has performance status 0 , 1 , 2 Eastern Cooperative Oncology Group ( ECOG ) Performance Scale Must least 18 year age Has nonsecretory multiple myeloma Has prior antimyeloma therapy within 2 week prior study Day 1 Has receive prior therapy antiprogrammed cell death 1 receptor ( antiPD1 ) , antiprogrammed deathligand 1 ( antiPDL1 ) , antiPDL2 , antiCD137 , anticytotoxic Tlymphocyteassociated antigen4 ( CTLA4 ) antibody ( include ipilimumab antibody drug specifically target Tcell costimulation checkpoint pathway ) . Has receive prior treatment daratumumab antiCD38 therapy previously Has undergone prior organ allogeneic hematopoetic stem cell transplantation Has receive autologous stem cell transplantation ( ASCT ) within 12 week date randomization . Has receive prior treatment monoclonal antibody within 5 halflives Study Day 1 Has receive investigational agent within 28 day 5 halflives ( whichever longer ) Study Day 1 Has receive live , attenuated vaccine within 30 day prior Study Day 1 Has chronic obstructive pulmonary disease ( COPD ) force expiratory volume 1 second ( FEV1 ) 50 % predict normal Has moderate severe persistent asthma within past 2 year uncontrolled asthma classification . Is positive human immunodeficiency virus ( HIV ) , chronic active hepatitis B active hepatitis A C Has prior history malignancy , MM , unless subject free disease â‰¥ 5 year ( exception Basal cell carcinoma skin , Squamous cell carcinoma skin , Carcinoma situ cervix , Carcinoma situ breast , Incidental histologic find prostate cancer [ T1a T1b ] prostate cancer curative ) Has clinical evidence central nervous system ( CNS ) pulmonary leukostasis , disseminate intravascular coagulation , CNS multiple myeloma Has clinically significant cardiac disease Is female pregnant , nursing , breastfeeding , intend become pregnant participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Phase 2</keyword>
	<keyword>Open-Label</keyword>
	<keyword>Durvalumab</keyword>
	<keyword>Daratumumab</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Relapsed Refractory ( RRMM )</keyword>
	<keyword>FUSION MM-003</keyword>
	<keyword>PD-L1</keyword>
</DOC>